14 DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1B-INFECTED NULL RESPONDERS OR INELIGIBLE/INTOLERANT TO PEGINTERFERON/RIBAVIRIN
- 30 April 2012
- journal article
- abstracts
- Published by Elsevier in Journal of Hepatology
- Vol. 56, S7-S8
- https://doi.org/10.1016/s0168-8278(12)60028-2
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: